Isosorbide: here's the fair price
This is what US pharmacies pay, on average, for isosorbide. Use it to spot a fair cash price, and feel good about asking for one.
Isosorbide Mononit Er 30 Mg Tb
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Isosorbide Mononit Er 30 Mg Tb. Pharmacies pay about $2.14 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| ISOSORBIDE MONONIT ER 30 MG TBGeneric | $0.07 per tablet or capsule | $2.14 | 10/21/2026 |
| ISOSORBIDE MONONIT ER 60 MG TBGeneric | $0.10 per tablet or capsule | $2.92 | 10/21/2026 |
| ISOSORBIDE DINITRATE 5 MG TABGeneric | $0.16 per tablet or capsule | $4.80 | 10/21/2026 |
| ISOSORBIDE MONONIT ER 120 MGGeneric | $0.17 per tablet or capsule | $5.01 | 10/21/2026 |
| ISOSORBIDE DINITRATE 10 MG TABGeneric | $0.17 per tablet or capsule | $5.06 | 10/21/2026 |
| ISOSORBIDE DINITRATE 20 MG TABGeneric | $0.19 per tablet or capsule | $5.55 | 10/21/2026 |
| ISOSORBIDE DINITRATE 30 MG TABGeneric | $0.26 per tablet or capsule | $7.88 | 10/21/2026 |
| ISOSORBIDE MONONIT 20 MG TABGeneric | $2.15 per tablet or capsule | $64.50 | 10/21/2026 |
| ISOSORBIDE MONONIT 10 MG TABGeneric | $2.19 per tablet or capsule | $65.58 | 10/21/2026 |
| ISOSORBIDE DINITRATE 40 MG TABGeneric | $3.36 per tablet or capsule | $100.85 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
INDICATIONS AND USAGE Isosorbide Mononitrate Tablets USP are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
Common side effects (FDA label)
ADVERSE REACTIONS Headache is the most frequent side effect and was the cause of 2% of all dropouts from controlled-clinical trials. Headache decreased in incidence after the first few days of therapy. The following table shows the frequency of adverse reactions observed in 1% or more of subjects in 6 placebo-controlled trials, conducted in the United States and abroad. The same table shows the frequency of withdrawal for these adverse reactions. In many cases the adverse reactions were of uncertain relation to drug treatment. Frequency Of Adverse Reactions (Discontinuations)* 6...
Drug interactions (from the label)
Drug Interactions Concomitant use of isosorbide mononitrate with phosphodiesterase inhibitors in any form is contraindicated (see CONTRAINDICATIONS ). Concomitant use of isosorbide mononitrate with riociguat, a soluble guanylate cyclase stimulator, is contraindicated (see CONTRAINDICATIONS ). The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. Alcohol, in particular, has been found to exhibit additive effects of this variety. Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. Dose adjustments of either class of agents may be necessary.
Warnings (from the label)
WARNINGS Amplification of the vasodilatory effects of isosorbide mononitrate by sildenafil can result in severe hypotension. The time course and dose dependence of this interaction have not been studied. Appropriate supportive care has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion. The benefits of isosorbide mononitrate in patients with acute myocardial infarction or congestive heart failure have not been established. Because the effects of isosorbide mononitrate are difficult to terminate rapidly, this drug is not recommended in these settings. If isosorbide mononitrate is used in these...
Source: FDA drug label via openFDA, label effective 2026-03-27. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.